PCI to Share Expertise in Serialization and Handling of Potent Drugs at CPhI

Pharmaceutical provider PCI Pharma Services announced that it will be participating in two Speakers Corner slots at the ICSE Exhibitor Showcase taking place at CPhI 2016.

On Oct. 4 (13:30), David O’Connell, director of Pharmaceutical Development, PCI Pharma Services, will present on key elements for the safe handling and manufacture of solid dose potent molecules. The session will outline the complexities of safe processing of highly potent products and key considerations when choosing an outsourcing partner including regulatory requirements.

“The pharmaceutical landscape continues to evolve with R&D pipelines developing new chemical entities for a wide range of disease states. The market has seen a shift towards more specialist medicines such as oncological and neurological products, in turn leading to an increase in the number of potent compounds requiring expert management,” O’Connell commented in a press statement. “With the complexities involved in the management of potent molecules and the regulatory requirements to ensure safe handling, it is imperative to use the right partner for successful development and manufacturing.”

On Oct. 5 (12:00), Ian Parsonage, senior director of Global Serialization, PCI Pharma Services will give a presentation on the key considerations, lessons learned, and best practices for global serialization strategy and implementation.

“With drug counterfeiting on the rise globally and regulatory deadlines fast approaching, the pharmaceutical supply chain will soon be at critical point to ensure patient safety. From drug manufacturers to distributors, supply chain partners need to make crucial decisions to upgrade production lines in compliance with traceability deadlines,” noted Parsonage. “I’m looking forward to sharing insights and best practices on how to execute a serialization strategy at the event.”

Source: PCI, Stand 3B16